Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP1139 | DOI: 10.1530/endoabs.41.EP1139

1Department of Endocrinology and Metabolism (Reina Sofia University Hospital, Córdoba), Cordoba, Andalucia, Spain; 2Department of Nuclear Medicine (Reina Sofia University Hospital, Córdoba), Cordoba, Andalucia, Spain.


Background: The management of patients with differentiated thyroid cancer (DTC) has been changing in recent years and aggressiveness of treatment depends on the risk of persistent or recurrent disease.

Objective: The aim of this study was to assess the efficacy of low doses of Radioactive Iodine (RAI;131I) therapy in patients with DTC.

Methods: We retrospectively evaluated all patients who were diagnosed with DTC (n=213) at a tertiary hospital center in Cordoba (Spain), between January 2000 and December 2013. In all patients included, initial treatment consisted of total or subsequent completion thyroidectomy, with or without lymphadenectomy, RAI ablation therapy at a dose of 30 mCi (n=17) or ≥100 mCi: 100 mCi (n=143), 150 mCi (n=5), 200 mCi (n=4). Demographic and clinical variables were compared between both groups of RAI therapy.

Results: Seventeen patients received a low dose of 131I (10♀; 7♂; 100% papillary). All subjects were classified as low risk of recurrence according to the revised ATA guidelines. Differences were found in the main prognostic factor as aggressive histological criteria (P=0.014), pTNM Stage (P=0.045), stimulated thyroglobulin (Stim-Tg) measured at 6–12 months (P=0.007). Statistically significant differences were not found in age (<45 or ≥45 years), sex, histology, total thyroidectomy or subsequent completion, neck lymphadenectomy, and the number of adverse effects. The hospitalization time was lower in the group of patients who received 30 mCi (6 hours us ≥48 hours; P<0.001). All of 17 patients had no evidence of disease after an average follow-up of 3.59 years. Up to now, recurrence has been detected in none of them.

Conclusions: Therapy with low doses of 131I (30 mCi) is an effective treatment in patients with low-risk of recurrence with de advantage of having a lower hospitalization time.

Article tools

My recent searches

No recent searches.